Teresa Bair compensation by year
Kura Oncology Summary Compensation Table · the one fiscal year held| Component | FY2024 |
|---|---|
| Salary | $468,520 |
| Bonus | $0 |
| Stock awards | $710,400 |
| Option awards | $816,451 |
| Non-equity incentive | $246,207 |
| Pension and deferred compensation | $0 |
| All other | $30,294 |
| Total | $2,271,872 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kura Oncology, Inc. DEF 14A filed April 11, 2025, accession 0000950170-25-053335, and prior-year filings.
How this page was built: the Kura Oncology, Inc. filed document, accession 0000950170-25-053335. Every figure is read from that document and cited to the page and table it appears in. Filed April 11, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 146,700 | $1,277,757 | — |
| RSU | 46,250 | $402,838 | — |
| RSU | 17,344 | $151,066 | — |
| Option | 40,000 | — | $17.51 |
| Option | 75,157 | — | $11.99 |
| Option | 71,303 | — | $15.36 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Kura Oncology, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Kura Oncology’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Troy Wilson | President and Chief Executive Officer | $6,239,098 |
| Stephen Dale | Former Chief Medical Officer | $2,508,675 |
| Kathleen Ford | Chief Operating Officer | $2,501,838 |
| Teresa Bair · this page | Chief Legal Officer and Secretary | $2,271,872 |
The full Kura Oncology compensation record
free company briefThis page is one person within Kura Oncology's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Kura Oncology proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Kura Oncology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.